Aim Recently increased attention and interest for Acinetobacterbaumanniiare the result of the occurrence of multidrug resistant (MDR), extensive drug resistant (XDR) and pandrug resistant (PDR) isolates around the world. The aim of this study was to examine the resistance of A. baumannii isolates to antimicrobials in Clinical Centre University of Sarajevo, Bosnia and Herzegovina. Methods Two hundred and fifty-seven A.baumannii isolates were collected between July 2011 and June 2012 in different wards and from different clinical samples.Multidrug resistant, XDR and PDR were defined according to international expert proposal for interim standard definitions for acquired resistance. Results A total of 257A. baumannii isolates showed eleven different patterns of resistance,of which ten patterns corresponded to MDR and one corresponded to XDR (sensitive only to colistin). Multidrug resistant and XDR strains were the most common at Intensive Care Units andsurgical departments. The largest numbers of isolates were found in wound swabs, blood and bronchial aspirate. Conclusion This is the first report of XDR A. baumannii in the 2000-bed Clinical Centre University of Sarajevo, Bosnia-Herzegovina. Although XDR strains have been detected,the resistance to colistinhasnot. The elevated prevalence of these strains indicates that local antibiotic prescription policies should be revised and infection prevention and control should be improved.
Perez F, Hujer A, Hujer K, Decker B, Rather P, Bonomo R. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007. p. 3471–84.
2.
Fournier P, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006. p. 692–9.
3.
Maragakis L, Perl T. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008. p. 1254–63.
4.
Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistantbacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012. p. 268–81.
5.
The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters.
6.
Evans B, Hamouda A, Towner K, Amyes S. OXA-51-like β-lactamases and their association with particular epidemic lineages of Acinetobacter baumannii. ClinMicrobiol Infect. 2008. p. 268–75.
7.
Camp C, Tatum O. A review of Acinetobacter baumannii as a highly successful pathogen in times of war. LabMedicine. 2010. p. 649–57.
8.
Ml JG. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect. 2005. p. 868–73.
9.
Acosta J, Merino M, Viedma E, Poza M, Sanz F, Otero J, et al. Multidrug-resistant Acinetobacter baumannii harboring OXA-24 carbapenemase. Spain. Emerg Infect Dis. 2011. p. 1064–7.
10.
Stoeva T, Higgins P, Bojkova K, Seifert H. Clonal spread of carbapenem-resistant OXA-23-positive Acinetobacter baumannii in a Bulgarian university hospital. Clin Microbiol Infect. 2008. p. 723–7.
11.
Liakopoulos A, Miriagou V, Katsifas E, Karagouni A, Daikos G, Tzouvelekis L, et al. Identification of OXA-23-producing Acinetobacter baumannii in Greece, 2010 to 2011. Euro Surveill. 2012.
12.
Popolo D, Giannouli A, Triassi M, Brisse M, Zarrilli S, R. Molecular epidemiologicalinvestigation of multidrug-resistant Acinetobacter baumannii strains in four Mediterranean countries with a multilocus sequence typing scheme. Clin Microbiol Infect. 2011. p. 197–8.
13.
Goic-Barisic I, Bedenic B, Tonkic M, Novak A, Katic S, Kalenic S, et al. Occurrence ofOXA-107 and ISAba1 in carbapenem-resistant isolates of Acinetobacter baumannii from Croatia. J Clin Microbiol. 2009. p. 3348–9.
14.
Bazargani A, Hashemizadeh Z. Bacteremia due to multidrug-resistant (MDR) and extended-spectrum beta-lactamase (ESBL) producing Acinetobacter baumannii. Afr JMicrobiol Res. 2011. p. 3483–6.
15.
Dhabaan G, Hamimah H, Shorman M. Emergence of extensive drug-resistant Acinetobacter baumannii in North of Jordan. Afr J Microbiol Res. 2011. p. 1070–5.
16.
Srinivasan V, Rajamohan G, Pancholi P, Stevenson K, Tadesse D, Patchanee P, et al. Genetic relatedness and molecular characterization of multidrug resistant Acinetobacterbaumannii isolated in central Ohio. Ann Clin Microbiol Antimicrob. 2009. p. 21.
17.
Lin M, Chang K, Lan C, Chou J, Kuo J, Chang C, et al. Molecular epidemiology and antimicrobial resistance determinants of multidrug-resistantAcinetobacter baumannii in five proximal hospitals in Taiwan. Jpn J InfectDis. 2011. p. 222–7.
18.
He C, Xie Y, Zhang L, Kaang M, Tao C, Chen Z, et al. Increasing imipenem resistance and dissemination of the ISAba1associated blaOXA-23 gene among Acinetobacterbaumannii isolates in an intensive care unit. J Med Microbiol. 2011. p. 337–41.
19.
Kuo S, Chang S, Wang H, Lai J, Chen P, Shiau Y, et al. Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program BMC Infectious Diseases. 2012. p. 200.
20.
Alireza JN, Masoomeh S, Van Belkum A, Ehsanollah GR. Nosocomial outbreak of extensively and pan drug-resistant Acinetobacter baumannii in Tertiary Hospital in central part of Iran. Jundishapur J Microbiol. 2013. p. 9892.
21.
Eser O, Ergin A, Tunckanat F, Hasscelik G. In vitro activity of tigecycline as a therapeutic against multidrug-resistant Acinetobacter spp. New Microbiol. 2008. p. 535–42.
22.
Zhang J, Zhu W, Tian S, Chu Y, Chen B. Clinical and epidemiologicaldescription of imipenem-resistant Acinetobacter baumannii causing nosocomialinfections in a regional teaching hospital in China. Afr J Microbiol Res. 2011. p. 1527–31.
23.
Hammami S, Ghozzi R, Saidani M, Redjeb S. Carbapenem-resistant Acinetobacterbaumannii producing the carbapenemase OXA-23 in Tunisia. Tunis Med. 2011. p. 638–43.
24.
Mireya U, Martí P, Xavier K, Miguel C, Magda M, C. Nosocomial infections in paediatric and neonatal intensive care units. J Infect. 2007. p. 212–20.
25.
Playford E, Craig J, Iredell J. Carbapenem-resistant Acinetobacter baumanniiin intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect. 2007. p. 204–11.
26.
Nowak P, Paluchowska P, Budak A. Distribution of blaOXA genes among carbapenemresistant Acinetobacter baumannii nosocomial strains in Poland. New Microbiol. 2012. p. 317–25.
27.
Wilks M, Wilson A, Warwick S, Price E, Kennedy D, Ely A, et al. Control of an outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus colonization and infection in an intensive care unit (ICU) without closingthe ICU or placing patients in isolation. Infect Control Hosp Epidemiol. 2006. p. 654–8.
28.
Mostofi S, Mirnejad R, Masjedian F. Multi-drug resistance in Acinetobacter baumannii strains isolated from the clinical specimens of three hospitals in Tehran-Iran. Afr Jmicrobiol Res. 2011. p. 4467–70.
29.
Choi S, Choo E, Kwak Y, Kim M, Jun J, Kim M, et al. Clinical characteristics and outcomes of bacteremia caused by Acinetobacter species other than A. baumannii: comparison with A. baumannii bacteremia. J Infect Chemother. 2006. p. 380–6.
30.
Mostachio A, Van Der Heidjen I, Rossi F, Levin A, Costa S. Multiplex PCR for rapid detection of genes encoding oxacillinases and metallo-βlactamases in carbapenem-resistant Acinetobacter spp. J Med Microbiol. 2009. p. 1522–4.
31.
Uskudar G, Kilic A, Gozen A, Bedir O, Basustaoglu A. Proceedings of 21 st European Congress of ClinicalMicrobiology and Infectious Diseases (ECCMID)/27 th International Congress of Chemotherapy (ICC). Clin Microbiol Infect. p. 134–5.
32.
Wareham D, Bean D, Khanna P, Hennessy E, Krahe D, Ely A, et al. Bloodstream infection due to Acinetobacter spp. epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis. 2008. p. 607–12.
33.
Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill. 2008. p. 1–11.
34.
Lin Y, Hsia K, Chen Y, Sheng W, Chang S, Liao M, et al. Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan. Antimicrob Agents Chemother. 2010. p. 2078–84.
35.
Goic-Barisic I, Bedenic B, Tonkic M, Katic S, Kalenic S, Punda-Polic V. First report of molecular characterization of carbapenem-resistant Acinetobacter baumannii in different intensive care units in University hospital Split. Croatia. J Chemother. 2007. p. 416–8.
36.
Bogiel T, Kwiecinska-Pirog J, Jachna-Sawicka K, Gospodarek E. Carbapenem-resistant Acinetobacter baumannii strains. Med Dosw Microbiol. 2010. p. 119–26.
37.
Mcgowan J. Resistance in nonfermenting gramnegative bacteria:multidrug resistance to the maximum. Am J Med. 2006. p. 29–36.
38.
European Centre for Disease Prevention and Control/European MedicinesAgency. ECDC/EMEA joint technical report: the bacterial challenge:time to react. 2009.
39.
Boucher H, Talbot G, Bradley J, Gilbert D, Rice L, Scheld M, et al. Bad bugs, no drugs: noESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009. p. 1–12.
40.
Manchanda V, Sanchaita S, Singh N, Multidrug R, Acinetobacter. J Glob Infect Dis. 2010. p. 291–4.
41.
Gales A, Jones R, Sader H. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme. Clin Microbiol Infect. 2006. p. 315–21.
42.
Souli M, Kontopidou F, Koratzanis E, Antoniadou A, Giannitsioti E, Evangelopoulou P, et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother. 2006. p. 3166–9.
43.
Henwood C, Gatward T, Warner M, James D, Stockdale M, Spence R, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother. 2002. p. 479–87.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
